Amir Zeb

Dr. Amir Zeb

Xinjiang Medical University, Ürümqi, Xinjiang, China
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MLMengjia Li
Mengjia Li
YZYongzheng Zhang
Yongzheng Zhang
AZAmir Zeb
Amir Zeb
YWYang Wu
Yang Wu
CFCheng Lu Feng
Cheng Lu Feng
Angiotensin-converting enzyme 2 (ACE2), a functional receptor for SARS-CoV, now appears likely to mediate 2019-nCoV entry into human cells. However, inhibitors such as PAP-1 and bergamottin have been discovered; both of them can preferentially bind to ACE2, prevent RBD Spike S protein from binding to ACE2, and reduce the binding sites for RBD Spike S protein. In addition, we investigated the binding energy of PAP-1 and bergamottin with ACE2 through molecular docking with bio-layer interferometry (BLI) and found relatively high binding affinity (KD = 48.5 nM, 53.1 nM) between the PAP-1 and bergamottin groups. In addition, the nanomolar fraction had no effect on growth of the AT-II cell, but 150 µM PAP-1 and 75 µM bergamottin inhibited the proliferation of AT-II cells in vitro by 75% and 68%, respectively. Meanwhile, they significantly reduced ACE2 mRNA and proteins by 67%, 58% and 55%, 41%, respectively. These results indicate that psoralen compounds PAP-1 and bergamottin binding to ACE2 protein could be further developed in the fight against COVID-19 infection during the current pandemic. However, attention should be paid to the damage to human alveolar type II epithelial cells.


9 September 2025 in Journal of Computational Biophysics and Chemistry
Verified
Journal Article
Closed access
HFHaris Faraz
Haris Faraz
AKAshraf Ullah Khan
Ashraf Ullah Khan
BRBushra Rehman
Bushra Rehman
AUAman Ullah
Aman Ullah
SKSalman Khan
Salman Khan
AUAmin Ullah
Amin Ullah

1 January 2026 in PPAR Research
Verified
Journal Article
Open access
Sabi Ur RehmanSabi Ur Rehman
Sabi Ur Rehman
FRFazal Ur Rehman
Fazal Ur Rehman
Shafi Ullah KhanShafi Ullah Khan
Shafi Ullah Khan
AZAmir Zeb
Amir Zeb
SASaleha Ashfaq
Saleha Ashfaq
WHWaheed Ullah Hafiz
Waheed Ullah Hafiz
Background: The peroxisome proliferator‐activated receptors (PPARs) and nuclear factor‐ κ B (NF‐ κ B) signaling axis serves as master molecular interface governing metabolic homeostasis and inflammatory resolution. Dysregulated reciprocal repression between PPAR‐ α / γ and NF‐ κ B contributes to chronic inflammatory diseases, metabolic syndrome, and malignancy. Synthetic full agonists (e.g., thiazolidinediones and fibrates) are associated with clinical liabilities including adipogenesis, fluid retention, hepatotoxicity, and cardiovascular adverse effects, underscoring the need for safer modulators. Objective and Rationale: This structured narrative review provides a rigorous mechanistic synthesis of plant derived phytochemicals with selective PPAR modulator (SPPARM) like pharmacology. We elucidate how distinct chemical classes may achieve targeted NF‐ κ B transrepression with reduced transcriptional liability, summarize available ligand receptor binding data, and critically evaluate translational hurdles. Methods: A structured narrative review was conducted using a systematic style literature search across PubMed/MEDLINE, Scopus, and Web of Science from January 2000 through March 2026. In line with PRISMA 2020 principles for transparent reporting, original research articles were prioritized according to evidence type (clinical, preclinical, in vivo, and in vitro/in silico), with emphasis on pharmacodynamic metrics, binding kinetics (K i , EC 50 , and IC 50 ), receptor dependency validation (knockout, antagonism), and pharmacokinetic data. Results: Chemically diverse phytochemicals including flavonoids, neolignans, stilbenoids and terpenoids exhibit partial or subtype selective PPAR agonism in reporter and binding assays. Mechanistically, many favor anti‐inflammatory transrepression over full coactivator‐dependent transactivation, with evidence for corepressor recruitment and inhibition of NF‐ κ B nuclear translocation in selected models. However, integrated analysis reveals a persistent disconnect between submicromolar in vitro potency and negligible systemic exposure of free parent compound (low C max , extensive glucuronidation/sulfation), compounded by frequent reliance on unvalidated docking simulations and PPAR‐independent NF‐ κ B inhibition. Conclusion: Phytochemicals with SPPARM‐like pharmacology represent a promising but unvalidated paradigm for nonsteroidal inflammation control. Realizing their potential will require next‐generation delivery systems (e.g., liposomes, nanoemulsions, and cyclodextrin complexes), mandatory genetic or pharmacological receptor validation, and biomarker‐driven clinical trials that document target engagement at achievable human exposure levels.